A clinical trial for efficacy and safety on carbon-ion radiotherapy and concurrent GEM chemotherapy for locally advanced pancreatic cancer

A clinical trial for efficacy and safety on carbon-ion radiotherapy and concurrent GEM chemotherapy for locally advanced pancreatic cancer - Carbon-ion radiotherapy and GEM for locallyadvanced pancreatic cancer

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000024695

Enrollment

Registered

2016-11-04

Start date

2016-12-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Locally advanced pancreatic cancer

Interventions

Carbon-ion 55.2Gy(RBE)/12fraction/3weeks+ Gemcitabine 1000mg/m2 X 3times

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Radiographic diagnosis of pancreatic invasive ductal carcinoma 2. Histological and/or cytological diagnosis of pancreas adenocarcinoma within 60 days of registration 3.No distant metastasis 4. invasion of the superior mesenteric, celiac, and hepatic arteries 5. Active inflammatory bowel disease or active gastric/duodenal ulcer 6. Age 18-80 years. 7. Zubrod performance status of 0-2,

Exclusion criteria

Exclusion criteria: 1 Invasion of the mucosal layer by endoscopic diagnosis 2.displacement of digestive tracts by Radiographic diagnosis 3 Ascites by Radiographic diagnosis 4.Placement of a metal stent for relief of biliary obstruction 5. Prior treatment for pancreatic cancer for longer than 90days

Design outcomes

Primary

Measure	Time frame
2-year overall survival rate	—

Countries

Japan

Contacts

Public ContactShigeru Yamada

National Institutes for Quantum and Radiological Science and Technology QST Hospital

yamada.shigeru@qst.go.jp043-206-3306

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026